67-6

21/93

51) Inomata T: A New Immunotherapy Using Regulatory T-Cells for High-Risk Corneal Transplantation. Juntendo Medical Journal. 2017; 63: 2-7.52) Hua J, Inomata T, Chen Y, et al: Pathological conver-sion of regulatory T cells is associated with loss of allotolerance. Sci Rep. 2018; 8: 7059.53) Inomata T, Hua J, Di Zazzo A, et al: Impaired Function of Peripherally Induced Regulatory T Cells in Hosts at High Risk of Graft Rejection. Sci Rep. 2016; 6: 39924.54) Ogawa M, Inomata T, Shiang T, et al: Method for selec-tive quantification of immune and inflammatory cells in the cornea using flow cytometry. J Biol Methods. 2018; 5: e102.55) Tan X, Chen Y, Foulsham W, et al: The immunoregu-latory role of corneal epithelium-derived thrombos-pondin-1 in dry eye disease. Ocul Surf. 2018.56) Hua J, Stevenson W, Dohlman TH, et al: Graft Site Microenvironment Determines Dendritic Cell Traf-ficking Through the CCR7-CCL19/21 Axis. Invest Ophthalmol Vis Sci. 2016; 57: 1457-1467.57) Hasin Y, Seldin M, Lusis A: Multi-omics approaches to disease. Genome Biol. 2017; 18: 83.58) Ota M, Fujio K: Multi-omics approach to precision medicine for immune-mediated diseases. Inflamm Regen. 2021; 41: 23.59) Papalexi E, Satija R: Single-cell RNA sequencing to explore immune cell heterogeneity. Nature reviews Immunology. 2018; 18: 35-45.60) Dobrozsi S, Panepinto J: Patient-reported outcomes in clinical practice. Hematology Am Soc Hematol Educ Program. 2015; 2015: 501-506.61) Bennett AV, Jensen RE, Basch E: Electronic patient-re-ported outcome systems in oncology clinical practice. CA Cancer J Clin. 2012; 62: 337-347.62) Torous J, Kiang MV, Lorme J, et al: New Tools for New Research in Psychiatry: A Scalable and Custom-izable Platform to Empower Data Driven Smartphone Research. JMIR Ment Health. 2016; 3: e16.63) Kitazawa K, Deinhardt-Emmer S, Inomata T, et al: The Transmission of SARS-CoV-2 Infection on the Ocular Surface and Prevention Strategies. Cells. 2021; 10.64) Inomata T, Kitazawa K, Kuno T, et al: Clinical and Prodromal Ocular Symptoms in Coronavirus Disease: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020; 61: 29.65) Hood L, Friend SH: Predictive, personalized, preven-tive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011; 8: 184-187.66) Sagner M, McNeil A, Puska P, et al: The P4 Health Spectrum - A Predictive, Preventive, Personalized and Participatory Continuum for Promoting Healthspan. Prog Cardiovasc Dis. 2017; 59: 506-521.67) Tham YC, Husain R, Teo KYC, et al: New digital models of care in ophthalmology, during and beyond the COVID-19 pandemic. Br J Ophthalmol. 2021.529